In a recent study entitled “Comparison of MR/Ultrasound Fusion–Guided Biopsy With Ultrasound-Guided Biopsy for the Diagnosis of Prostate Cancer” researchers showed that by combining target magnetic resonance imaging (MRI) with ultrasound fusion biopsy, they can increase the efficiency of high-risk prostate cancer detection. The study was published in The Journal of the American Association (JAMA). Currently, prostate cancer diagnosis is performed by a standard biopsy, technically denominated as standard extended-sextant biopsy, where a random sample of the prostate is extracted for analysis. However, innovative techniques are emerging with the potential to enhance the efficiency of prostate cancer diagnosis, notably in those patients considered to be at high risk. One such techniques is the combination of targeted magnetic resonance (MR) with ultrasound fusion biopsy, characterized by the stacking of multiparametric magnetic resonance imaging (MP-MRI) in real time with a subsequent targeted biopsy of the areas revealed suspicious in the MP-MRI images. In this study, the authors compared the efficiency of diagnosis in intermediate- to high-risk prostate cancer patients using both targeted versus standard biopsy or the combination of the two techniques. The team performed a large-scale study selecting 1,003 men who had undergone either targeted or standard biopsy at the National Cancer Institute. Patients were previously submitted to blood tests and were found to have elevated levels of prostate-specific antigen (PSA) accompanied with an abnormal digital rectal exam, but negative prior biopsy results. Patients were submitted to multiparametric prostate magnetic resonance imaging and subsequent targeted MR/ultrasound fusion biopsy or standard biopsy.